Search

everythinglearnresearchcommunity

for

Search:↓

New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.

Stem Cell Educator therapy helps regrow hair and improve life quality in alopecia areata patients.

People with Alopecia Areata have lower vitamin D levels.

Patients with alopecia areata have lower zinc levels, and zinc supplements might help.

People with hair loss conditions experience more anxiety, depression, and a lower quality of life than those without these conditions.

Alopecia areata significantly worsens quality of life, suggesting a need for mental health support.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Some people with heavy hair shedding might actually have a hidden form of alopecia, which can be identified by specific hair changes.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Personality traits and anxiety affect hair loss patients' quality of life.

Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.

Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.

Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Patients with alopecia areata feel less regret about treatment decisions when they are involved in the decision-making process.

Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.

Apremilast did not work for treating severe alopecia areata.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

People with alopecia areata may have a higher risk of hearing loss.

Wigs significantly improve the well-being of people with severe hair loss.

Patients with Type 1 diabetes should be screened for pernicious anemia.

Patients with severe alopecia areata have higher levels of MIF, which decrease after successful treatment.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.

Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.

COVID-19 doesn't make alopecia areata worse.

The guidelines recommend effective systemic treatments for alopecia areata in Korea.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.